重药控股：子公司签订GLP-1R激动剂全球许可协议

Core Viewpoint - Chongqing Yaoyou Pharmaceutical, a subsidiary of Zhongyao Holdings, has signed a Collaboration and License Agreement with Pfizer, granting exclusive global rights for the development, use, production, and commercialization of the GLP-1R agonist YP05002 and related products [1] Group 1 - The agreement includes an upfront payment of $150 million, potential development milestone payments of up to $350 million, and sales milestone payments of up to $1.585 billion, along with royalties based on agreed percentages [1] - As of the announcement date, YP05002 is in Phase I clinical trials in Australia [1]